Generex Biotechnology Announces Co-Authorship of Publications With Johns Hopkins...

Generex Biotechnology Announces Co-Authorship of Publications With Johns Hopkins
University and Stallergenes S.A.

WORCESTER, Mass., Jan. 22, 2008 (PRIME NEWSWIRE) -- Generex Biotechnology
Corporation (Nasdaq:GNBT) announced today the publication of two scientific
abstracts arising from collaborations between the Company's Antigen Express
immunotherapy subsidiary and Johns Hopkins University (www.jdu.edu) and
Stallergenes S.A. (www.stallergenes.com). The focus of Antigen Express is on
proprietary immunotherapeutic technologies that modulate the body's response to
foreign and endogenous agents by modulating their interaction with CD4+ T helper
cells.

The paper, co-authored with Johns Hopkins University, is titled "Short peptide
sequences mimic HLA-DM functions" and is scheduled for publication in the
peer-reviewed journal Molecular Immunology (and is currently available online at
www.sciencedirect.com). The study confirms the mechanism of CD4+ T helper
stimulation by Ii-Key sequences. Antigen Express has exploited this Ii-Key
activity to generate immunogenic vaccine peptides targeting a variety of serious
unmet medical needs. The study was co-authored by Dr. Minzhen Xu, Vice President
of Biology at Antigen Express.

The second paper, co-authored with Stallergenes, is titled "Single cell
assessment of allergen-specific T cell responses with MHC class II peptide
tetramers: Methodological aspects" and is scheduled for publication (and is
currently available online at www.karger.com/iaa) in Volume 146, Issue No. 2,
2008 of the peer-reviewed journal the International Archives of Allergy and
Immunology. The study demonstrated that T helper cells that are activated to
respond to specific allergens can be identified with high sensitivity ex vivo
using Ii-Key hybrids. This is a similar strategy to that being employed by the
Antigen Express to identify patients in the earliest stages of Type 1 diabetes.
This study was co-authored by Drs. Robert Humphreys, the founder of Antigen
Express, and Eric von Hofe, the President of Antigen Express. Stallergenes is a
European biopharmaceutical company focused on the treatment by desensitization
of allergy-related respiratory conditions.

Antigen Express has a number of peptide vaccines in development for infectious
agents, oncology, and autoimmune indications that are based upon theist
proprietary Ii-Key technology platform. The most advanced is an
immunotherapeutic vaccine currently in Phase II clinical trials in patients with
breast cancer. That peptide has been shown to be safe and well-tolerated in all
patients. Immunological responses consistent with antigen-specific T helper cell
stimulation have also been observed.

About Generex

Generex is engaged in the research, development, and commercialization of drug
delivery systems and technologies. Generex has developed a proprietary platform
technology for the delivery of drugs into the human body through the oral cavity
(with no deposit in the lungs). The Company's proprietary liquid formulations
allow drugs typically administered by injection to be absorbed into the body by
the lining of the inner mouth using the Company's proprietary RapidMist device.
The Company's flagship product, oral insulin (Generex Oral-lyn), which is
available for sale in Ecuador for the treatment of patients with Type-1 and
Type-2 diabetes and which was approved for sale in India in October 2007, is in
various stages of clinical development around the world. Antigen Express is a
wholly owned subsidiary of Generex. The core platform technologies of Antigen
Express comprise immunotherapeutics for the treatment of malignant, infectious,
allergic, and autoimmune diseases. For more information, visit the Generex
website at www.generex.com or the Antigen Express website at
www.antigenexpress.com.

Safe Harbor Statement: This release and oral statements made from time to time
by Generex representatives concerning the same subject matter may contain
``forward-looking statements'' within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements can be identified by
introductory words such as ``expects,'' ``plans,'' ``intends,'' ``believes,''
``will,'' ``estimates,'' ``forecasts,'' ``projects'' or words of similar
meaning, and by the fact that they do not relate strictly to historical or
current facts. Forward-looking statements frequently are used in discussing
potential product applications, potential collaborations, product development
activities, clinical studies, regulatory submissions and approvals, and similar
operating matters. Many factors may cause actual results to differ from
forward-looking statements, including inaccurate assumptions and a broad variety
of risks and uncertainties, some of which are known and others of which are not.
Known risks and uncertainties include those identified from time to time in the
reports filed by Generex with the Securities and Exchange Commission, which
should be considered together with any forward-looking statement. No
forward-looking statement is a guarantee of future results or events, and one
should avoid placing undue reliance on such statements. Generex undertakes no
obligation to update publicly any forward-looking statements, whether as a
result of new information, future events or otherwise. Generex cannot be sure
when or if it will be permitted by regulatory agencies to undertake additional
clinical trials or to commence any particular phase of clinical trials. Because
of this, statements regarding the expected timing of clinical trials cannot be
regarded as actual predictions of when Generex will obtain regulatory approval
for any ``phase'' of clinical trials. Generex claims the protection of the safe
harbor for forward-looking statements that is contained in the Private
Securities Litigation Reform Act.

-0-
CONTACT: CEOcast, Inc.
Gary Nash
212-732-4300

American Capital Ventures, Inc.
For Generex:
Howard Gofstrand
305-918-7000